Editorial Comment - 20/03/18
Doi : 10.1016/j.urology.2017.08.068
Zaina P. Qureshi, Ph.D., M.P.H., M.S. a, b, c
a Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC
b The Southern Network on Adverse Reaction (SONAR) Project, The South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, SC
c WJB Dorn VA Medical Center, Columbia, SC
Oliver Sartor, M.D.
Departments of Urology and Medicine, Tulane University School of Medicine, New Orleans, LA
Charles L. Bennett, M.D., Ph.D., M.P.P. d, e, f, g
d Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC
e The Southern Network on Adverse Reaction (SONAR) Project, The South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, SC
f WJB Dorn VA Medical Center, Columbia, SC
g The Hollings National Cancer Institute Designated Cancer Center, Medical University of South Carolina, Charleston, WV
El texto completo de este artículo está disponible en PDF.
© 2017
The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 113
P. 144-145 - mars 2018 Regresar al número
Artículo precedente
- Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study
- Christopher J.D. Wallis, Raj Satkunasivam, Refik Saskin, Symron Bansal, Girish S. Kulkarni, Urban Emmenegger, Robert K. Nam
- Reply
- Christopher J.D. Wallis, Robert K. Nam
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?